RedHill Biopharma (RDHL) Non-Current Assets (2012 - 2025)

RedHill Biopharma (RDHL) has reported Non-Current Assets for 14 consecutive years, with $18.8 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Non-Current Assets rose 206.87% year-over-year to $18.8 million in Q4 2025; TTM through Dec 2025 was $18.8 million, a 206.87% increase from a year earlier, with the FY2025 full-year figure at $18.8 million, up 206.87% from the prior year.
• Non-Current Assets was $18.8 million for Q4 2025 at RedHill Biopharma, up from $5.8 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $105.2 million in Q2 2021 and troughed at $5.8 million in Q2 2025.
• A 5-year average of $39.9 million and a median of $13.4 million in 2023 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets sank 90.53% in 2023 and surged 206.87% in 2025, its largest moves.
• Over 5 years, Non-Current Assets stood at $92.0 million in 2021, then dropped by 20.72% to $73.0 million in 2022, then slumped by 90.53% to $6.9 million in 2023, then slipped by 11.22% to $6.1 million in 2024, then surged by 206.87% to $18.8 million in 2025.
• The last three Non-Current Assets figures came in at $18.8 million (Q4 2025), $5.8 million (Q2 2025), and $6.1 million (Q4 2024), per Business Quant data.